{
    "Trade/Device Name(s)": [
        "ARIES MRSA Assay"
    ],
    "Submitter Information": "Luminex Corporation",
    "510(k) Number": "K191742",
    "Predicate Device Reference 510(k) Number(s)": [
        "K133605"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NQX"
    ],
    "Summary Letter Date": "September 25, 2019",
    "Summary Letter Received Date": "July 1, 2019",
    "Submission Date": "June 28, 2019",
    "Regulation Number(s)": [
        "21 CFR 866.1640"
    ],
    "Regulation Name(s)": [
        "Antimicrobial Susceptibility Test Powder"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "mecA gene",
        "mecC gene",
        "orfX complex gene",
        "SCCmec junction region",
        "Sample Processing Control (SPC)"
    ],
    "Specimen Type(s)": [
        "Nasal swabs"
    ],
    "Specimen Container(s)": [
        "Liquid Amies Elution Swab (ESwab)",
        "Sample Processing Tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ARIES System",
        "ARIES M1 System"
    ],
    "Method(s)/Technology(ies)": [
        "Real-time PCR",
        "Qualitative nucleic acid amplification",
        "Fluorescent probe detection",
        "Melting curve analysis"
    ],
    "Methodologies": [
        "Qualitative PCR-based DNA detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "System",
        "Cassette",
        "Protocol file",
        "Software",
        "Sample processing tube"
    ],
    "Document Summary": "FDA 510(k) summary for ARIES MRSA Assay, a qualitative real-time PCR test for detection of MRSA DNA from nasal swabs using ARIES System",
    "Indications for Use Summary": "Qualitative in vitro diagnostic test for direct detection of methicillin-resistant Staphylococcus aureus (MRSA) DNA from nasal swabs in patients at risk for nasal colonization; intended to aid in the prevention and control of MRSA infections in healthcare settings",
    "fda_folder": "Microbiology"
}